#### UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPRO	VAL
OMB Number:	3235-0287
Estimated average but	rden
hours per response	0.5

longer subject to Section 16. Form 4 or Form 5

### STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

obligations may continue. See Instruction Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

	Responses)															
1. Name and Address of Reporting Person * HIGGINS JOHN L				2. Issuer Name and Ticker or Trading Symbol LIGAND PHARMACEUTICALS INC [LGND]						D]	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) _X_Director10% Owner					
(Middle) 5980 HORTON STREET, SUITE 405				3. Date of Earliest Transaction (Month/Day/Year) 05/09/2022							X Officer (give title below) Other (specify below)  Chief Executive Officer					
(Street)					4. If Amendment, Date Original Filed(Month/Day/Year)							6. Individual or Joint/Group Filing(Check Applicable Line)  X_Form filed by One Reporting Person  Form filed by More than One Reporting Person				
EMERYVILLE, CA 94608																
(City)		(State)	(Zip)				Table	I - Non-D	erivativ	e Securit	ies Acquire	d, Disposed	of, or Benefici	ally Owned		
1.Title of Security (Instr. 3)		2. Transaction Date (Month/Day/Yea	2A. Deemed Execution Date, if any (Month/Day/Year)		Date, if	(Instr. 8		4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		of (D) O				Form: Direct (D)	7. Nature of Indirect Beneficial Ownership	
					Code	e V	Amount	(A) or (D)	Price		(Instr. 4)					
Common St	ock		05/09/2022				M		8,000	A	\$ 21.92 3	48,593			D	
			Table I	I - Deriv	ative	Securi	ties Acai	uired. Disi	osed of	or Bene	ficially Ow	ned				
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if	4. Transac Code	outs,	5. Num Deriva Securit Acquir or Disp (D) (Instr.	hber of tive ties red (A) posed of	uired, Dispositions, contions, contions, contions, contions, continued to the continued to	onvertil cercisabl Date	ble secur e and	7. Title and	d Amount of g Securities	8. Price of Derivative Security (Instr. 5)	9. Number of Derivative Securities Beneficially Owned Following Reported	Owners Form of Derivat Security Direct ( or Indir	ove Owners (Instr. 4 D)
Derivative Security	Conversion or Exercise Price of Derivative	Date	3A. Deemed Execution Date, if any	4. Transac Code	outs, etion	5. Num Deriva Securit Acquir or Disp (D)	harrants, haber of tive ties red (A) posed of 3, 4,	6. Date Expiration	ercisabla Date ay/Year)	ble secur e and	7. Title and Underlying	d Amount of g Securities	Derivative Security	Derivative Securities Beneficially Owned Following	Owners Form of Derivat Security Direct ( or Indir	chip of Indire f Benefic Owners y: (Instr. 4
Derivative Security	Conversion or Exercise Price of Derivative Security	Date	3A. Deemed Execution Date, if any	4. Transac Code (Instr. 8	outs, etion	5. Num Deriva Securit Acquir or Disp (D) (Instr.: and 5)	narrants, her of tive ties red (A) possed of 3, 4,	options, c 6. Date Estation (Month/D)  Date	ercisable Date ay/Year)  Expire Date	ble secur e and	7. Title and Underlying (Instr. 3 and	Amount of g Securities d 4)  Amount or Number of Shares	Derivative Security	Derivative Securities Beneficially Owned Following Reported Transaction	Owners Form of Derivat Security Direct ( or Indir (s) (I) (Instr. 4	chip of Indire f Benefic Owners y: (Instr. 4

## **Reporting Owners**

	Relationships					
Reporting Owner Name / Address	Director	10% Owner	Officer	Other		
HIGGINS JOHN L 5980 HORTON STREET, SUITE 405 EMERYVILLE, CA 94608	X		Chief Executive Officer			

# **Signatures**

By: Charles S. Berkman For: John L. Higgins	05/10/2022
**Signature of Reporting Person	Date

## **Explanation of Responses:**

\* If the form is filed by more than one reporting person, see Instruction 4(b)(v).

- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- The notes are convertible at any time prior to the close of business on November 14, 2022 (1) during any fiscal quarter (and only during such fiscal quarter) commencing after September 30, 2018, if, for at least 20 trading days (whether or not consecutive) during the 30 consecutive trading day period ending on the last trading day of the immediately preceding fiscal quarter, the last reported
- (1) sale price of the Issuer?s common stock on such trading day is greater than 130% of the conversion price on such trading day; (2) during the five business day period immediately following any 10 consecutive trading day period, in which the trading price per \$1,000 principal amount of notes was less than 98% of the product of the last reported sale price of our common stock on such trading day and the conversion rate on each such trading day; or (3) upon the occurrence of certain specified corporate events as specified in the indenture governing the notes.
- (2) Grant to reporting person of options, exercisable over a 4-year period measured from the date of grant, 12-1/2% after six months, then 1/48th of the Option Shares per month thereafter. The date of grant was 02/15/13.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.